

PUBBLICAZIONI

- 1) R. Mariani-Costantini, **R. Agresti**, M.I. Colnaghi, S. Mènard, S. Andreola and F. Rilke: Characterization of the specificity by immunohistology of a monoclonal antibody to a novel epithelial antigen of ovarian carcinomas.
Path. Res. Pract. 180: 169-180, 1985.
- 2) M.I. Colnaghi, S. Mènard, M.G. Da Dalt, **R. Agresti**, G.Cattoretto, S. Andreola, G. Di Fronzo, M. Del Vecchio, L.Verderio, N. Cascinelli and F. Rilke: A multiparametric study by monoclonal antibodies in breast cancer. In: R.L. Ceriani (ed.) Immunological approaches to the diagnosis and therapy of breast cancer. pp 21-32, Plenum Publishing Corp., 1987.
- 3) M.I. Colnaghi, **R. Agresti**, S. Mènard, M.G. Da Dalt, G.Cattoretto, S. Andreola, G. Di Fronzo, M. Del Vecchio, L.Verderio, N. Cascinelli, M. Greco and F. Rilke: Monoclonal antibodies as indicators of tumor progression in breast cancer.
Adv. Exp. Med. Biol. 233: 319-327, 1987.
- 4) M.I. Colnaghi, **R. Agresti**, S. Menard, M.G. Da Dalt, G. Cattoretto, S. Andreola, G. Di Fronzo, M. Del Vecchio, L. Verderio, N. Cascinelli, M. Greco, F. Rilke: Cancer metastasis: biological and biochemical mechanism and clinical aspects. In Monoclonal antibodies as prognostic indicators of tumor progression in breast cancer. Edited by G. Prodi et al. NY, Plenum press, 1988.
- 5) **R. Agresti**, R. Alzani, S. Andreola, V. Bedini, S. Gianì, S. Mènard, F. Rilke and M.I. Colnaghi: Histopathological characterization of a novel monoclonal antibody, MLuC1, reacting with lung carcinomas.
Tumori 74: 401-410, 1988.
- 6) F.Crippa, GL.Buraggi, **R.Agresti**, E.Seregini, A.Chiti, E.Bombardieri, M.Greco, S.Andreola, U.Veronesi: Pre operative axillary radio-immuno scintigraphy of breast cancer.
J Nucl Biol Med 38: 189-190, 1994
- 7) N. Cascinelli, M. Greco, E. Leo, **R. Agresti**, S. Andreola: Monoclonal antibodies MBr1 and MBr8: Predictors of response of oophorectomy in advanced breast cancers.
Tumori 74: 309-312, 1988
- 8) M. Vaglini, M. Santinami, **R. Agresti**, M. Maniezzo, N.Cascinelli: Hyperthermic antitumor perfusion in extracorporeal circulation for advanced melanoma of the extremities.
Proceedings of XXVI World Congress of International College of Surgeons, vol.VIII pp.261-263, 1988.
- 9) M. Greco, D. Galluzzo, A. Testori, M. Baldini, **R. Agresti**, N.Cascinelli: Recidive locali dopo chirurgia radicale del carcinoma mammario. (Local recurrences after radical surgery in breast cancer). Proceedings XIII Congresso Nazionale Società Italiana Chirurgia Oncologica, p 183-185, Monduzzi ed., 1989.
- 10) D. Galluzzo, S. Marchini, **R. Agresti**, V. Delledonne, M. Greco: La chemioterapia nel trattamento del melanoma maligno disseminato. (Chemotherapy for disseminated malignant melanoma).
Stampa Med. Eur. 10: 81-91, 1990.
- 11) V. Sacchini, A. Luini, S. Tana, L. Lozza, V. Galimberti, M.Merson, **R. Agresti**, P. Veronesi, M. Greco: Quantitative and qualitative cosmetic evaluation after conservative

treatment for breast cancer. Eur. J. Cancer 27: 1395-1400, 1991

12) S. Bergonzi, M. Barberini, G. Piragine, G. Viganotti, C. Ferranti, **R. Agresti**, G. Coopmans de Yoldi: Regressione dopo chemioterapia di metastasi mammarie da melanoma maligno: analisi mammografica di un caso. (Disappearance of breast metastases from malignant melanoma after chemotherapy. Mammographic study of one case).

Radiol. Med. 84: 153-156, 1992.

13) S. Zurrada, C. Bartoli, G. Colleoni, **R. Agresti**, I. Del Prato, F. Nolè and E. Bajetta: Classic Kaposi sarcoma: report of 90 cases.

J. Dermat. 19: 548-552, 1992.

14) D. Galluzzo, S. Marchini, **R. Agresti**, A.R. Conti, G. Farante, A. Rancati, G.S. Begnis M. Greco: La quimioterapia en el tratamiento del melanoma maligno diseminado.

Oncologia 15: 132-139, 1992.

15) V. Sacchini, G. Coopmans de Yoldi, A. Luini, C. Ferranti, **R. Agresti**, G. Piragine, V. Galimberti, B. Salvadori: Localizzazione pre-operatoria di lesioni mammarie clinicamente non palpabili.

Argomenti di oncologia 13: 267-277, 1992.

16) U. Veronesi, S. Andreola, **R. Agresti**, V. Galimberti, S. Zurrada : The examination of resection margins with conservative surgery. What is the value? in L. Wise, Johnson H jr ed: Breast cancer: controversies in the management. pp. 165-168. Futura publ. co. 1994.

17) F. Crippa, E. Seregni, **R. Agresti**, E. Bombardieri and G.L. Buraggi : Bone scintigraphy in breast cancer: a ten-year follow-up study.

J. Nucl. Biol. Med. 37: 57-61, 1993.

18) V. Sacchini, M. Greco, G. Farante, A. Rancati, A. Luini, A. Grisotti, **R. Agresti**, C. Maanon, S.E. Bronberg : Resultados esteticos en cirugia mamaria conservadora.

Rev. Venez. Oncol. 5:24-29,1993.

19) M. Greco, V. Sacchini, **R. Agresti**, A. Luini, M. Del Vecchio, R. Raselli : Quadrantectomy is not a disfiguring operation for small breast cancer.

The Breast 3: 3-7, 1994.

20) S. Zurrada, **R. Agresti**, G. Cefalo : Juvenile Classic Kaposi's Sarcoma: a report of two cases, one with family history.

Pediat. Hemat. Oncol. 11. 409-416,1994.

21) A. Luini, V. Sacchini, **R. Agresti** : Il trattamento delle lesioni non palpabili della mammella. In: P. Pietri, E. Trabucchi, U. Salvadori, U. Veronesi (eds.) Carcinoma della mammella. Attualità e prospettive. Edizioni Minerva Medica, Torino, 1994; 69-73.

22) U. Veronesi, G. Bonadonna, S. Zurrada, V. Galimberti, M. Greco, C. Brambilla, A. Luini, S. Andreola, F. Rilke, R. Raselli, M. Merson, V. Sacchini and **R. Agresti**: Conservation Surgery after Primary Chemotherapy in Large Carcinomas of the Breast.

Ann. Surg. 222: 612-618, 1995.

23) V. Sacchini, A. Luini, **R. Agresti**, M. Greco, A. Manzari, L. Mariani, R. Zucali, B. McCormick : The influence of radiotherapy on cosmetic outcome after breast conservative surgery.

Int. J. Radiat. Oncol. Biol. Phys. 33: 59-64, 1995

- 24) F. Crippa, **R. Agresti**, E. Seregni, A. Chiti, E. Bombardieri, M. Greco, S. Andreola, G.L. Buraggi, U. Veronesi: Pre-operative axillary radioimmunosciintigraphy of breast cancer. Int. J. Oncol. 6: 791-795, 1995.
- 25) M. Greco, **R. Agresti**, R. Raselli : Conservative treatment of breast cancer : Milan experience. Acta Chir Austr. 27: 238-242, 1995.
- 26) M. Greco, S. Zurrada, V. Galimberti, **R. Agresti**: Surgical implications of pre-operative chemotherapy in large-size breast cancer. In: Figuera Fo A., Novais-Diaz E., Salvador-Silva E.M., Barros A. (eds): Mastology-Breast diseases. Elsevier Science B.V., pagg.193-196, 1995.
- 27) L. Maffioli, **R. Agresti**, A. Chiti, F. Crippa, M. Gasparini, M. Greco, E. Bombardieri: Prone scintimammography in patients with non-palpable breast lesions. Anticancer Res. 16: 1269-1274, 1996.
- 28) E. Bombardieri, F. Crippa, L. Maffioli, A. Chiti, M.R. Castellani, M. Greco, **R. Agresti**, A. Bogni, C. Chiesa, V. De Sanctis, S. Massaron, C. Pascali: Axillary lymph node metastases detection with nuclear medicine approaches in patients with newly diagnosed breast cancer: can positron emission tomography (PET) with 18F-FDG be considered as the best method? Int. J. Oncol 8: 693-699, 1996.
- 29) M. Greco, **R. Agresti**, R. Raselli, R. Giovanazzi and U. Veronesi : Axillary dissection can be avoided in breast cancer selected patients: analysis of 401 cases. Anticancer Res 16: 3913-3918, 1996.
- 30) A. Chiti, **R. Agresti**, L. Maffioli, G. Tomasic, G. Savelli, F. Crippa, S. Pilotti, M. Greco, E. Bombardieri: Breast cancer staging using [99mTc]-Sestamibi and [111In]-Pentretotide single photon emission tomography. Eur J Nucl. Med. 24: 192-196, 1997
- 31) A. Chiti, **R. Agresti**, G. Savelli, R. Giovanazzi, M. Greco, E. Bombardieri: Radionuclide imaging of unsuspected multifocal breast cancer. Surgical implications. The Breast 6:386-387,1997
- 32) A.Moliterni, E.Tarenzi, G.Capri, M.Terenziani, A.Bertuzzi, G.Grasselli, **R.Agresti**, M.Greco, B.Salvadori, S.Pilotti, F.Lombardi, P.Valagussa, G.Bonadonna and L.Gianni: Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Sem Oncol 24(suppl 17) S17-10-S17-14,1997
- 33) A.Chiti, L.Maffioli, **R.Agresti**, A.Spinelli, G.Savelli, M.R.Castellani, R.Giovanazzi, M.Greco, E.Bombardieri: Axillary node metastasis detection in breast cancer with 99Tc-sestamibi and 111-In-pentretotide. Tumori 83: 537-538, 1997.
- 34) L.Maffioli, E.Seregni, A.Chiti, S.Nerini Molteni, F.Crippa, C.Botti, A.Bogni, **R.Agresti**, E.Bombardieri: Radiopharmaceuticals for breast cancer imaging. Tumori 83: 512-514, 1997.
- 35) F.Crippa, **R.Agresti**, V.Delledonne, C.Pascali, A.Bogni, C.Chiesa, V.DeSanctis, M.Schiavini, D.Decise, E.Bombardieri: The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of National Cancer Institute of Milan. Tumori 83: 542-543, 1997.

- 36) F.Crippa, **R.Agresti**, E. Seregni, M.Greco, C.Pascali, C.Chiesa, V.DeSanctis, V.Delledonne, B.Salvadori, M.Leutner and E.Bombardieri: Prospective evaluation of Fluorine [18F]FDG PET in the presurgical staging of the axilla in breast cancer. J Nucl Med 39:4-8,1998
- 37) M.Greco, **R.Agresti**, R.Giovanazzi: Impact of diagnostic methods on therapeutic strategies. Q J Nucl Med 42:66-80,1998.
- 38) E. Bombardieri, F. Crippa, L. Maffioli, A. Draisma, A. Chiti, **R. Agresti**, M. Greco: Nuclear medicine approaches for detection of axillary lymph node metastases. Q J Nucl Med 42:54-65,1998.
- 39) S.Menard, P.Casalini, **R.Agresti**, S.Pilotti, A.Balsari: Proliferation of breast carcinoma during the menstrual phases. The Lancet 352:148-149,1998.
- 40) M. Greco, **R.Agresti**, R.Giovanazzi: Breast conservation following induction chemotherapy. In: J Cardoso da Silva (ed): 10th international congress on Senology-Breast Diseases. Monduzzi Ed. 275-281, 1998.
- 41) E. Seregni, S. Massaron, A. Martinetti, M.T. Illeni, D. Rovini, F. Belli, **R.Agresti**, M. Greco, N. Cascinelli, E. Bombardieri: S100 protein serum levels in cutaneous malignant melanoma. Oncology Reports 5:601-604,1998.
- 42) F. Crippa, E. Seregni, **R. Agresti**, C. Chiesa, C. Pascali, A. Bogni, D. Decise, V. De Sanctis, M. Greco, M.G. Daidone, E. Bombardieri: Association between [18F] Fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidin labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25: 1429-1434,1998.
- 43) A. Martinetti, E. Seregni, F. Belli, A. Mazzocchi, **R. Agresti**, M. Greco, E. Bombardieri: Evaluation of serum 2'-5' oligoadenylate synthetase (2'-5' oligoAS) and β 2 microglobulin (B2M) in patients with nodal metastases from cutaneous malignant melanoma treated with rIFN- α 2A. Anticancer Res 18:2027-2030,1998
- 44) Balsari A, Casalini P, Tagliabue E, Greco M, Pilotti S, **Agresti R**, Giovanazzi R, Alasio L, Rumio C, Cascinelli N, Colnaghi MI and Menard S: Fluctuation of HER2 expression in breast carcinomas during the menstrual cycle. Am J Path 155; 1543-1547, 1999.
- 45) Greco M, **Agresti R**, Cascinelli N, Casalini P, Giovanazzi R, Maucione A, Tomasic G, Ferraris C, Ammatuna M, Pilotti S, Menard S: Breast cancer patients treated without axillary surgery: clinical implications and biological analysis. Ann Surg 232: 1-7, 2000
- 46) Ardini E, **Agresti R**, Tagliabue E, Greco M, Aiello P, Liang Tung Y, Menard S and Sap J: Expression of protein tyrosine phosphatase alpha (RTP α) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth *in vitro* and *in vivo*. Oncogene 19; 4979-87, 2000
- 47) Maffioli LS, Seregni E, Chiesa C, Nerini-Molteni S, Gerali A, Bombardieri E, Greco M, **Agresti R**: Detection of lymphnode metastases by lymphoscintigraphy with a tumour-

seeking tracer in breast cancer patients.
Eur J Nucl Med 27: 744-746, 2000.

48) Menard S, Agresti R, Tagliabue E, Somenzi G, Campiglio M, Ghirelli C, Balsari A: Proliferation of dormant HER-2 positive breast carcinoma cells by growth factors produced during wound healing of breast carcinomas. EACR XVI. Halkidiki – Hellas 137-138, 2000. (abstract)

49) Greco M, Gennaro M, Valagussa P, **Agresti R**, Ferraris C, Urban C, Ferrari B, Gianni L: Impact of nodal status on indication for adjuvant treatment in clinically node negative breast cancer. Ann Oncol 11; 1137-40, 2000

50) **Agresti R**, Asero S: Il linfonodo sentinella. In: Galante LE ed: La Salute del seno: dalla interpretazione dei sintomi alla lettura della diagnosi. Il Pensiero Scientifico Editore, 145-150, 2000.

51) Greco M, Crippa F, **Agresti R**, Seregini E, Gerali A, Giovanazzi R, Micheli A, Asero S, Ferraris C, Gennaro M, Bombardieri E, Cascinelli N: Axillary lymph node staging in breast cancer by fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 93; 630-5, 2001.

52) Menard S, Casalini P, Campiglio M, Pupa S, **Agresti R** and Tagliabue E: HER2 overexpression in various tumor types. Ann Oncol 12; S 15-19, 2001

53) Menard S, Fortis S, Castiglioni F, **Agresti R**, Balsari A: HER2 as a prognostic factor in breast cancer. Oncology 61 suppl S2; 67-72, 2001.

54) Tagliabue E, **Agresti R**, Ghirelli C, Morelli D, Menard: Early relapse of premenopausal patients after surgery for node-positive breast carcinoma. Breast Cancer Res Treat 72, 185-187, 2002

55) Forti S, Scanlan MJ, Invernizzi A, Castiglioni F, Pupa S, **Agresti R**, Fontanelli R, Morelli D, Old LJ, Pupa SM, Menard S: identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum. Breast Cancer Res Treat 73, 245-256, 2002

56) Tagliabue E, **Agresti R**, Carcanciu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Menard S: Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362, 527-33, 2003

57) Pupa SM, Argraves WS, Forti S, Casalini P, Berno V, **Agresti R**, Aiello P, Invernizzi A, Baldassari P, Twal WO, Mortarini R, Anichini A, Menard S: Immunological and pathobiological roles of fibulin-1 in breast cancer. Oncogene 23, 2153-60, 2004

58) Crippa F, Geral A, Alessi A, **Agresti R**, Bombardieri E: FDG-PET for axillary lymphnode staging in primary breast cancer. Eur J Nucl Med Mol Imaging Suppl 1, S97-102, 2004

59) Fierabracci P, Pinchera A, Tonacchera M, Agretti P, De Marco G, Albertini S, Conforti G, Seregini E, **Agresti R**, Grasso L, Giani C: Absence of interference of serum IgGs from patients with breast cancer and thyroid autoimmunity on the function of human

iodide symporter gene stably transfected in CHO cells.
J endocrinol Invest 27, 862-5, 2004

60) Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S, **Agresti R**, Giovanazzi R, Pilotti S, Bertario L, Ravagnani F, Dragani TA: FGFR4 Gly388Arg polymorphism and prognosis of breast cancer and colorectal cancer.
Oncol Rep 14, 415-9, 2005

61) Tagliabue E, **Agresti R**, Casalini P, Mariani L, Carcangiu ML, Balsari A, Veronesi U, Menard S: Linking serviva of HER2-positive breast carcinoma patients with surgical invasiveness.
Eur J Cancer 42, 1057-61, 2006
(I primi due autori hanno egualmente contribuito nel presente lavoro)

62) Crippa F, Gerali A, Alessi A, **Agresti R**, Bombardieri E: The role of FDG-PET for axillary lymph node staging in primary breast cancer. In: Breast cancer: Nuclear medicine in diagnosis and therapeutics options. Bombardieri E, Bonadonna G, Gainni L eds. Springer, 158-65, 2008.

63) Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumor recurrence dynamics provides clues for tumour biology within the residual breast.
BMC Cancer 10, 656,2010

64) Trecate G, Manoukian S, Suman L, Vergnaghi D, Marchesini M, **Agresti R**, Ferraris C, Peissel B, scaramuzza D, Bergonzi S: Is there a specific magnetic resonance phenotype characteristic of hereditary breast cancer.
Tumori, 96, 363-84, 2010

63) Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, Piromalli D, **R.Agresti**: Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol 18, 125-33, 2011

64) Secreto G, Meneghini E, Venturelli E, Cogliati P, **Agresti R**, Ferraris C, Gion M, Zancan M, Fabricio AS, Berrino F, Cavalleri A, Micheli A: Circulating sex hormones and tumor characteristics in postmenopausal breast cancer patients. A cross-sectional study. Int J Biol Markers. 2011 Oct-Dec;26(4):241-6.

65) Belardi V, Fiore E, Giustarini E, Muller I, Sabatini S, Rosellini V, Seregni E, **Agresti R**, Marcocci C, Vitti P, Giani C. Is the risk of primary hyperparathyroidism increased in patients with untreated breast cancer?
J Endocrinol Invest. 2012 Aug 29.

66) Martelli G, Boracchi P, Ardoino I, Lozza L, Bohm S, Vetrella G, **Agresti R**. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Ann Surg. 2012 Dec;256(6):920-4.

67) Secreto G, Venturelli E, Meneghini E, Carcangiu ML, Paolini B, **Agresti R**, Pellitteri C, Berrino F, Gion M, Cogliati P, Saragò G, Micheli A. Androgen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers. BMC Cancer. 2012 Dec 14;12(1):599.

68) Demicheli R, Ardoino I, Ambrogi F, **Agresti R**, Biganzoli E. Significance of ipsilateral breast tumor recurrence after breast conserving treatment: role of surgical removal. Chin J Cancer Res. 2013 Feb;25(1):22-31. doi: 10.3978/j.issn.1000-9604.2013.01.03

69) Silvestrini R, Martelli G, Miceli R, **Agresti R**, Veneroni S, Daidone MG. Cell proliferation of the primary tumor predicts ipsilateral axillary node disease in elderly breast cancer patients.
Int J Biol Markers. 2013 Apr 23;28(1):e24-31. doi: 10.5301/JBM.2013.10574

70) Trecate G, **Agresti R**, Suman L, Vergnaghi D, Valeri B, Marchesini M, Ferranti C, Panizza P. What is specific in hereditary breast cancer? High T2 signal intensity as a new semeiotic pattern?
Eur J of Radiology 8151 (2012) S165-S170